Mark S. LeDoux, M.D., Ph.D.
Department of Neurology Department of Anatomy and Neurobiology
Division of Movement Disorders
Dystonia and Huntington Disease Clinics
Movement Disorders Research Laboratories
The University of Tennessee Health Science Center
855 Monroe Avenue
Suite 415 Link Building
Memphis, TN 38163
Phone: (901) 448-1662
Fax: (901) 448-7440
Email: Mark S. LeDoux
- M.D. Institution: Louisiana State University School of Medicine
- Ph.D. Institution: University of Alabama, Birmingham, Department of Neuroscience
- Residency Training: University of Alabama at Birmingham; University of Tennessee Health Science Center
- Neurology - Mark S. LeDoux
- Wesley Neurology Clinic
- To support our research efforts in the fight against Parkinson disease, dystonia and other movement disorders, give an online gift, and specify "LeDoux Laboratory."
- Genetics and pathobiology of primary dystonia
- Using vertebrate and invertebrate models, human lymphoblastoid cell lines and stable transfected cell lines, we study the cellular and systems biology of dystonia-associated proteins (torsinA, THAP1, caytaxin, carbonic anhydrase 8 and epsilon-sarcoglycan).
- Genetic contributions to late-onset primary dystonia are being examined with candidate gene, genome-wide and gene expression studies.
- Mechanisms of neurodegeneration in Parkinson disease: several members of the tetrahydroisoquinoline (TIQ) family of monoamine alkaloids can be formed from dopamine or its oxidized metabolites and may be involved in the pathogenesis of monoaminergic cell death in Parkinson disease. To examine the potential role of TIQs in monoaminergic cell death, we have used enantiomeric-selective high-performance liquid chromatography with electrochemical detection, liquid chromatography with tandem mass spectroscopy, cell culture studies of neurotoxicity and assays of mitochondrial membrane potential.
- Clinical trials of therapeutic interventions for movement disorders (dystonia, Huntington disease, Parkinson disease, restless legs syndrome)
- Anatomy and computational organization of motor systems
- The neural networks mediating suprasegmental control of the blink reflex and spontaneous blinking remain poorly understood. Viral transneuronal tracing is being used to define the integrated premotor cortical and subcortical control of levator palpebrae and orbicularis oculi motoneuron activity.
- In isolation or via interactions with striatal-thalamo-cortical pathways, olivocerebellar structures play a critical role in disorders of motor control such as ataxia and dystonia. Using neurophysiological and molecular tools, we are dissecting the relative roles of individual network elements in the positive and negative signs characteristic of individual movement disorders.
Clinical Subspecialty Expertise
Adult and Pediatric Movement Disorders, Botulinum Toxin for Dystonia and Spasticity, Deep Brain Stimulation
- Murgai AA, LeDoux MS. Memantine-induced Myoclonus in a Patient with Alzheimer Disease. Tremor Other Hyperkinet Mov (N Y). 2015 Aug 14;5:337. doi: 10.7916/D8ZG6RD9. eCollection 2015. PubMed PMID: 26317045; PubMed Central PMCID: PMC4548970.
- Li C, Fitzgerald ME, Del Mar N, Cuthbertson-Coates S, LeDoux MS, Gong S, Ryan JP, Reiner A. The identification and neurochemical characterization of central neurons that target parasympathetic preganglionic neurons involved in the regulation of choroidal blood flow in the rat eye using pseudorabies virus, immunolabeling and conventional pathway tracing methods. Front Neuroanat. 2015 Jun 2;9:65. doi: 10.3389/fnana.2015.00065. eCollection 2015. PubMed PMID: 26082687; PubMed Central PMCID: PMC4451581.
- Pfeiffer RF, LeDoux MS. Levodopa-induced lateral jaw deviation dystonia. Parkinsonism Relat Disord. 2015 Jul;21(7):808. doi: 10.1016/j.parkreldis.2015.02.012. Epub 2015 Apr 25. PubMed PMID: 25956205.
- Riede T, Zhao Y, LeDoux MS. Vocal development in dystonic rats. Physiol Rep. 2015 Apr;3(4). pii: e12350. doi: 10.14814/phy2.12350. PubMed PMID: 25907786; PubMed Central PMCID: PMC4425958.
- Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015 Jan;14(1):39-47. doi: 10.1016/S1474-4422(14)70262-5. Epub 2014 Nov 14. PubMed PMID: 25467848.
- Luciano AY, Jinnah HA, Pfeiffer RF, Truong DD, Nance MA, LeDoux MS. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord. 2014 Dec;20(12):1423-6. doi: 10.1016/j.parkreldis.2014.09.029. Epub 2014 Oct 5. PubMed PMID: 25406829; PubMed Central PMCID: PMC4254189.